Bavarian Nordic presents new preclinical data for Covid-19 vaccine

Bavarian Nordic's first clinical studies with a vaccine for Covid-19 are almost ready. Ahead of launch, the firm has received a batch of positive preclinical data. This confirms the potential, according to Bavarian Nordic's CEO Paul Chaplin.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Bavarian Nordic is getting ready for its first in-human trial with the vaccine, which the firm in-licensed from Adaptvac, and now, in the first round, new data has arrived.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs